DDInter1458 DDInter1397
Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes.
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Phenylpropanolamine {u} (Compound) binds {v} (Gene) SLC6A2
SLC6A2 {u} (Gene) is bound by {v} (Compound) Paroxetine
Phenylpropanolamine {u} (Compound) upregulates {v} (Gene) FOXO4
FOXO4 {u} (Gene) is upregulated by {v} (Compound) Paroxetine
Phenylpropanolamine {u} (Compound) downregulates {v} (Gene) PRR7
PRR7 {u} (Gene) is downregulated by {v} (Compound) Paroxetine
Phenylpropanolamine {u} (Compound) causes {v} (Side Effect) Dyskinesia
Dyskinesia {u} (Side Effect) is caused by {v} (Compound) Paroxetine
Phenylpropanolamine {u} (Compound) binds {v} (Gene) SLC6A3
SLC6A3 {u} (Gene) is associated with {v} (Disease) bipolar disorder
bipolar disorder {u} (Disease) is palliated by {v} (Compound) Paroxetine
Phenylpropanolamine {u} (Compound) upregulates {v} (Gene) FOXO4
FOXO4 {u} (Gene) regulates {v} (Gene) LIPA
LIPA {u} (Gene) is upregulated by {v} (Compound) Paroxetine
Phenylpropanolamine {u} (Compound) downregulates {v} (Gene) PRR7
PRR7 {u} (Gene) is regulated by {v} (Gene) CDKN1A
CDKN1A {u} (Gene) is upregulated by {v} (Compound) Paroxetine
Phenylpropanolamine {u} (Compound) downregulates {v} (Gene) CSRP1
CSRP1 {u} (Gene) is regulated by {v} (Gene) CHRM1
CHRM1 {u} (Gene) is bound by {v} (Compound) Paroxetine
Phenylpropanolamine {u} (Compound) downregulates {v} (Gene) NUP85
NUP85 {u} (Gene) regulates {v} (Gene) CDKN1A
CDKN1A {u} (Gene) is upregulated by {v} (Compound) Paroxetine
Phenylpropanolamine {u} (Compound) resembles {v} (Compound) Metaraminol
Metaraminol {u} (Compound) downregulates {v} (Gene) CLTB
CLTB {u} (Gene) is downregulated by {v} (Compound) Paroxetine
Phenylpropanolamine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Paroxetine (Compound)
Phenylpropanolamine (Compound) upregulates FOXO4 (Gene) and FOXO4 (Gene) is upregulated by Paroxetine (Compound)
Phenylpropanolamine (Compound) downregulates PRR7 (Gene) and PRR7 (Gene) is downregulated by Paroxetine (Compound)
Phenylpropanolamine (Compound) causes Dyskinesia (Side Effect) and Dyskinesia (Side Effect) is caused by Paroxetine (Compound)
Phenylpropanolamine (Compound) binds SLC6A3 (Gene) and SLC6A3 (Gene) is associated with bipolar disorder (Disease) and bipolar disorder (Disease) is palliated by Paroxetine (Compound)
Phenylpropanolamine (Compound) upregulates FOXO4 (Gene) and FOXO4 (Gene) regulates LIPA (Gene) and LIPA (Gene) is upregulated by Paroxetine (Compound)
Phenylpropanolamine (Compound) downregulates PRR7 (Gene) and PRR7 (Gene) is regulated by CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Paroxetine (Compound)
Phenylpropanolamine (Compound) downregulates CSRP1 (Gene) and CSRP1 (Gene) is regulated by CHRM1 (Gene) and CHRM1 (Gene) is bound by Paroxetine (Compound)
Phenylpropanolamine (Compound) downregulates NUP85 (Gene) and NUP85 (Gene) regulates CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Paroxetine (Compound)
Phenylpropanolamine (Compound) resembles Metaraminol (Compound) and Metaraminol (Compound) downregulates CLTB (Gene) and CLTB (Gene) is downregulated by Paroxetine (Compound)